FIG. 5.

SLAM has a more rapid cell surface turnover rate than CD46. Human 1A2 B-cell lymphoma cells were treated with tunicamycin, which inhibits N-linked glycosylation and migration of newly synthesized SLAM to the cell surface. At the times indicated, FACS analyses of SLAM and CD46 expression were performed. The mean fluorescence intensity was measured by gating on live cells and was expressed as the relative percentage of steady-state receptor expression on 1A2 cells (0 h). The data shown are the averages of three independent experiments, with the error bars representing the standard deviations.